Tom Jefferson has nicely widened the efficacity of a well-established
folk medicine, already renowned for its beneficial effects on mental
and emotional function, namely: Salisternuvir.
Etymology (from Latin)
"Salis": salt
"Ternum": pinch
"vir": Obligatory suffix required by Regulatory Authorities
Well done, Tom.
And Season's Greetings to all!
Ted.
On 23-Dec-2014 07:40:23 Tom Jefferson wrote:
> The label says:
>
> "Overall, subjects receiving RAPIVAB 600 mg experienced alleviation
> of their combined influenza symptoms a median of 21 hours sooner
> than those receiving placebo. The median time to recovery to normal
> temperature (less than 37°C) in the 600 mg group was approximately
> 12 hours sooner compared to placebo."
>
> "There is no evidence for efficacy of RAPIVAB in any illness caused
> by agents other than influenza viruses. Serious bacterial infections
> may begin with influenza-like symptoms or may coexist with or occur
> as complications during the course of influenza. RAPIVAB has not been
> shown to prevent such complications."
>
> It is also worth having a look at the press release.
>
> http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm
>
> noting the irrelevance of the opening CDC-like statement about
> hospitalisations for a drug which does not have evidence of affecting
> hospitalizations, complications etc.
>
> The harms bit is generic with gastrointestinal harms (like the other two
> NIs) and the mystification of psychiatric effects (which could be be
> confused with influenza symptoms and viceversa). We labelled these
> "compliharms" in our review.
>
> We have shown that in prophylaxis (where there is no influenza
> interference) there is increased risk of neuropsychiatric harms.
>
> All in all this means that the FDA press releases are to be taken with many
> pinches of salt.
>
>
> Tom.
>
> On 23 December 2014 at 08:29, Tom Jefferson <[log in to unmask]> wrote:
>
>> No, the same as Tamiflu and Zanamvir.
>>
>> The drugs have a central action probably acting on the hypothalamus and
>> bringing fever down. Their in vitro effect on influenza viruses does not
>> appear to have a practical impact in vivo.
>>
>> There is no other credible evidence of any other effect on any other
>> outcomes.
>>
>> I notice that there is nothing on harms.
>>
>> Happy Xmas to you all,
>>
>> Tom.
>>
>> On 22 December 2014 at 22:48, write words <[log in to unmask]> wrote:
>>
>>> Is this clinically relevant?
>>>
>>> From the press release
>>> <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm>
>>> :
>>>
>>> Rapivab's efficacy was established in 297 participants with confirmed
>>> influenza who were randomly assigned to receive Rapivab 300 milligrams
>>> (mg), Rapivab 600 mg or placebo. Overall, participants receiving Rapivab
>>> 600 mg had their combined influenza symptoms alleviated 21 hours sooner, on
>>> average, than those receiving placebo, which is consistent with other drugs
>>> in the same class. Those receiving Rapivab 600 mg also recovered to normal
>>> temperature approximately 12 hours sooner compared to placebo. Supportive
>>> trials confirmed these findings. However, efficacy could not be established
>>> in patients with serious influenza requiring hospitalization.
>>>
>>>
>>>
>>> -Christie
>>>
>>>
>>
>>
>> --
>> Dr Tom Jefferson
>> Medico Chirurgo
>> GMC # 2527527
>>
>
>
>
> --
> Dr Tom Jefferson
> Medico Chirurgo
> GMC # 2527527
-------------------------------------------------
E-Mail: (Ted Harding) <[log in to unmask]>
Date: 23-Dec-2014 Time: 18:21:40
This message was sent by XFMail
-------------------------------------------------
|